```checklist
SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*
Section/item
	Item No
	Description
	Addressed on page number
	Administrative information
	

	Title
	1
	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym
	Page 1
	Trial registration
	2a
	Trial identifier and registry name. If not yet registered, name of intended registry
	Page 1 (Clinicaltrials.gov identifier: NCT02689492)
	2b
	All items from the World Health Organization Trial Registration Data Set
	Not addressed
	Protocol version
	3
	Date and version identifier
	Not addressed
	Funding
	4
	Sources and types of financial, material, and other support
	Page 9 (Supported by Boehringer Ingelheim S.p.A, Italy)
	Roles and responsibilities
	5a
	Names, affiliations, and roles of protocol contributors
	Page 9 (Acknowledgements section)
	5b
	Name and contact information for the trial sponsor
	Page 9 (Boehringer Ingelheim Italy)
	

	5c
	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities
	Page 9 (Acknowledgements section)
	

	5d
	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)
	Page 9 (Acknowledgements section)
	Introduction
	

	

	

	Background and rationale
	6a
	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention
	Page 1-2
	

	6b
	Explanation for choice of comparators
	Not addressed
	Objectives
	7
	Specific objectives or hypotheses
	Page 1-2
	Trial design
	8
	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)
	Page 2 (observational study)
	Methods: Participants, interventions, and outcomes
	

	Study setting
	9
	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
	Page 2 (20 Italian pulmonary centers)
	Eligibility criteria
	10
	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
	Page 2-3
	Interventions
	11a
	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
	Not applicable (observational study)
	11b
	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)
	Not applicable (observational study)
	11c
	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)
	Not addressed
	11d
	Relevant concomitant care and interventions that are permitted or prohibited during the trial
	Not addressed
	Outcomes
	12
	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended
	Page 2-3
	Participant timeline
	13
	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)
	Page 4 (Table 1)
	Sample size
	14
	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations
	Page 2-3
	Recruitment
	15
	Strategies for achieving adequate participant enrolment to reach target sample size
	Not addressed
	Methods: Assignment of interventions (for controlled trials)
	

	Allocation:
	

	

	

	Sequence generation
	16a
	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions
	Not applicable (observational study)
	Allocation concealment mechanism
	16b
	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
	Not applicable (observational study)
	Implementation
	16c
	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions
	Not applicable (observational study)
	Blinding (masking)
	17a
	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how
	Not applicable (observational study)
	

	17b
	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participantâ€™s allocated intervention during the trial
	Not applicable (observational study)
	Methods: Data collection, management, and analysis
	

	Data collection methods
	18a
	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
	Page 2-4
	

	18b
	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
	Not addressed
	Data management
	19
	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
	Not addressed
	Statistical methods
	20a
	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol
	Page 3
	

	20b
	Methods for any additional analyses (eg, subgroup and adjusted analyses)
	Not addressed
	

	20c
	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)
	

Page 3
	Methods: Monitoring
	

	Data monitoring
	21a
	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed
	Not addressed
	

	21b
	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial
	Not addressed
	Harms
	22
	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct
	Not addressed
	Auditing
	23
	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor
	Not addressed
	Ethics and dissemination
	

	Research ethics approval
	24
	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval
	Page 2 (The study conformed to the Declaration of Helsinki. The local institutional ethics committees approved the work, and informed written consent was obtained from each participant.)
	Protocol amendments
	25
	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)
	Not addressed
	Consent or assent
	26a
	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)
	Page 2 (Informed written consent was obtained from each participant.)
	

	26b
	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable
	Not addressed
	Confidentiality
	27
	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial
	Not addressed
	Declaration of interests
	28
	Financial and other competing interests for principal investigators for the overall trial and each study site
	Page 9-10 (Conflict of interest statement)
	Access to data
	29
	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators
	Not addressed
	Ancillary and post-trial care
	30
	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation
	Not addressed
	Dissemination policy
	31a
	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions
	Not addressed
	

	31b
	Authorship eligibility guidelines and any intended use of professional writers
	Page 9 (Acknowledgements section)
	

	31c
	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code
	Not addressed
	Appendices
	

	

	

	Informed consent materials
	32
	Model consent form and other related documentation given to participants and authorised surrogates
	Not addressed
	Biological specimens
	33
	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable
	Not addressed
	
```
